Cagrilintide
Aliases: AM833 · CagriSema (sa semaglutidom)
Last verified: 2026-09-23
The short version
A long-acting amylin analogue — reduces appetite via the area postrema. The CagriSema combination (cagrilintide + semaglutide) in Phase III: ~−20% weight. Status: in clinical trials. Investigational; FDA application (CagriSema) filed Dec 2025, decision expected late 2026.
Identity & type
- Molecular type
- analog
- Origin
- A long-acting amylin analogue — reduces appetite via the area postrema.
Mechanism of action
Amylin/calcitonin receptor agonist → satiety via hindbrain pathways, slowed gastric emptying.
Dosing & routes
Official / clinical context
No approved official document exists for Cagrilintide. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Trials: 2.4 mg SC weekly (CagriSema fixed combination). As part of CagriSema: trial participants describe strong satiety with less nausea than pure GLP-1; the amylin pathway gives a different, "longer-lasting" satiety profile.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
As part of CagriSema: trial participants describe strong satiety with less nausea than pure GLP-1; the amylin pathway gives a different, "longer-lasting" satiety profile.
Protocol — official vs community
Official / label
Only studied as the fixed combination CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg, SC weekly) in the REDEFINE program.
- 01Titrated as the combination, mirroring semaglutide escalation
Duration: Trial-defined, chronic in design.
As of 2026, cagrilintide has essentially no standalone human protocol — its data exists almost entirely in combination.
Community (anecdotal)
Sold as standalone vials (0.25–1 mg weekly anecdotally), sometimes self-combined with semaglutide.
- Cycle:
- Continuous anecdotally.
- Break:
- None documented.
Self-assembled cagrilintide + semaglutide is not CagriSema: different ratio, titration and manufacturing standard.
Human evidence
Phase III REDEFINE 1/2 (CagriSema combination): −22.7% without diabetes, −15.7% with diabetes; REDEFINE-4 (head-to-head vs tirzepatide): −23%, non-inferiority endpoint missed. Novo filed the FDA application in December 2025.
Preclinical evidence
Preclinical literature preceded the clinical trials; details vary by compound.
Known risks
- GI side effects; generally milder profile than GLP-1s.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety in off-label use
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.